Yuriko Fukuta
A5035738937- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Long-Term Effects of COVID-19
- COVID-19 Impact on Reproduction
- Diabetic Foot Ulcer Assessment and Management
- Antibiotic Resistance in Bacteria
- COVID-19 and Mental Health
- Wound Healing and Treatments
- Blood groups and transfusion
- Antimicrobial Resistance in Staphylococcus
- Infective Endocarditis Diagnosis and Management
- Fungal Infections and Studies
- Streptococcal Infections and Treatments
- Healthcare Decision-Making and Restraints
- Traumatic Ocular and Foreign Body Injuries
- Psychosomatic Disorders and Their Treatments
- Legionella and Acanthamoeba research
- Healthcare cost, quality, practices
- Blood donation and transfusion practices
- Inflammasome and immune disorders
- Neutropenia and Cancer Infections
- HIV, Drug Use, Sexual Risk
- Antibiotics Pharmacokinetics and Efficacy
- Antenna Design and Analysis
- Bacterial Identification and Susceptibility Testing
Baylor College of Medicine
2021-2024
Harris Health System
2022
St. Luke's Hospital
2022
Ben Taub Hospital
2022
Weatherford College
2020
Wheeling Hospital
2018
University of Pittsburgh
2012-2013
Office of Infectious Diseases
2012
Polyclonal convalescent plasma may be obtained from donors who have recovered coronavirus disease 2019 (Covid-19). The efficacy of this in preventing serious complications outpatients with recent-onset Covid-19 is uncertain.
The ongoing evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants severely limits available effective monoclonal antibody therapies. Effective drugs are also supply limited. COVID-19 convalescent plasma (CCP) qualified for high levels effectively reduces immunocompetent outpatient hospitalization. Food and Drug Administration currently allows CCP the immunosuppressed. Viral-specific in can range 10- to 100-fold between donors, unlike uniform viral-specific...
Cytokines and chemokines play a critical role in the response to infection vaccination. We aimed assess longitudinal association of COVID-19 vaccination with cytokine chemokine concentrations trajectories among people SARS-CoV-2 infection. In this longitudinal, prospective cohort study, blood samples were used from participants enrolled multi-centre randomised trial assessing efficacy convalescent plasma therapy for ambulatory COVID-19. The was conducted 23 outpatient sites USA. (aged ≥18...
Abstract Background The efficacy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) convalescent plasma (CCP) for preventing infection in exposed, uninfected individuals is unknown. CCP might prevent when administered before symptoms or laboratory evidence infection. Methods This double-blinded, phase randomized, controlled trial (RCT) compared the and safety prophylactic high titer (≥1:320 by Euroimmun ELISA) with standard plasma. Asymptomatic participants aged ≥18 years close...
ABSTRACT BACKGROUND The efficacy of polyclonal high titer convalescent plasma to prevent serious complications COVID-19 in outpatients with recent onset illness is uncertain. METHODS This multicenter, double-blind randomized controlled trial compared the and safety SARS-CoV-2 placebo control symptomatic adults ≥18 years positive for regardless risk factors disease progression or vaccine status. Participants symptom within 8 days were enrolled, then transfused subsequent day. measured primary...
Approximately 20% of individuals infected with SARS-CoV-2 experienced long-term health effects, as defined PCC. However, it is unknown if there are any early biomarkers associated PCC or whether intervention treatments may decrease the risk In a secondary analysis randomized clinical trial, this study demonstrates that among outpatients SARS-CoV-2, increased IL-6 at time infection odds addition, treated early, within 5 days symptom onset, COVID-19 convalescent plasma, was trend for decreased...
Convalescent plasma, collected from donors who have recovered a pathogen of interest, has been used to treat infectious diseases, particularly in times outbreak, when alternative therapies were unavailable. The COVID-19 pandemic revived interest the use convalescent plasma. Large observational studies and clinical trials that executed during provided insight into how whereby high levels antibodies against administration early within time course disease are critical for optimal therapeutic...
Background. Methicillin-resistant Staphylococcus aureus (MRSA) is a major pathogen in hospital-acquired infections. MRSA-colonized inpatients who may benefit from undergoing decolonization have not been identified. Objective. To identify risk factors for MRSA infection among patients are colonized with at hospital admission. Design. A case-control study. Setting. 146-bed Veterans Affairs hospital. Participants. Case were those admitted January 2003 to August 2011 found be on admission and...
BACKGROUND. COVID-19 convalescent plasma (CCP) virus-specific antibody levels that translate into recipient posttransfusion sufficient to prevent disease progression are not defined.
Abstract Background COVID‐19 convalescent plasma (CCP) is an important therapeutic option for outpatients at high risk of hospitalization from SARS‐CoV‐2 infection. We assessed the safety outpatient CCP transfusions administered during clinical trials. Study Design and Methods analyzed data pertaining to transfusion‐related reactions two randomized controlled trials in U.S. that evaluated efficacy versus control various ambulatory settings. Multivariable logistic regression was used assess...
Monoclonal antibody and antiviral treatments for COVID-19 disease remain largely unavailable worldwide, existing monoclonal antibodies may be less active against circulating omicron variants. Although treatment with convalescent plasma (CCP) is promising, randomized clinical trials (RCTs) among outpatients have shown mixed results. We conducted an individual participant data meta-analysis from all outpatient CCP RCTs to assess the overall risk reduction all-cause hospitalizations by day 28...
ABSTRACT Early COVID-19 convalescent plasma (CCP) transfusion to outpatients with decreases progression hospitalization, but the mechanism of how CCP reduces severity is unknown. Among 882 participants transfused or control in a randomized controlled trial, 21 cytokines and chemokines were measured using electrochemiluminescence assays. Wilcoxon rank sum tests used evaluate difference between early (transfused within 5 days symptom onset) vs late 6–9 after at each visit. Linear mixed-effect...
An abstract is not available for this content so a preview has been provided. Please use the Get access link above information on how to content.
To provide information about the management of infected wounds in wound care settings.This continuing education activity is intended for physicians, physician assistants, nurse practitioners, and nurses with an interest skin care.After participating this educational activity, participant will:1. Identify a host factor that may predispose patient to infection as well characteristics each stage infection.2. Distinguish common organism causes early, acute infections explain preferred method...
ABSTRACT BACKGROUND The efficacy of SARS-CoV-2 convalescent plasma (CCP) for preventing infection in exposed, uninfected individuals is unknown. We hypothesized that CCP might prevent when administered before symptoms or laboratory evidence infection. METHODS This double-blinded, phase 2 randomized, controlled trial (RCT) compared the and safety prophylactic high titer (≥1:320) with standard plasma. Asymptomatic participants aged ≥18 years close contact exposure to a person confirmed...
ABSTRACT Background Post-COVID conditions (PCC) are common and have significant morbidity. Risk factors for PCC include advancing age, female sex, obesity, diabetes mellitus. Little is known about early treatment, inflammation, PCC. Methods Among 883 individuals with confirmed SARS-CoV-2 infection participating in a randomized trial of CCP vs. control plasma available biospecimens symptom data, the association between COVID cytokine levels was evaluated. Cytokine chemokine were assessed at...
Abstract Background Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) reduces hospitalizations among outpatients treated early after symptom onset. It is unknown whether CCP time to resolution outpatients. Methods We evaluated at day 14 by trial arm using an adjusted subdistribution hazard model, with hospitalization as a competing risk. also assessed the prevalence of clusters between treatments. Clusters were defined based on biologic clustering, impact ability work, and...
ABSTRACT BACKGROUND The COVID-19 convalescent plasma (CCP) viral specific antibody levels that translate into recipient post-transfusion sufficient to prevent disease progression is not defined. METHODS This secondary analysis correlated donor and hospitalization risk among unvaccinated, seronegative CCP recipients within the outpatient, double blind, randomized clinical trial compared control plasma. majority of arm hospitalizations (15/17, 88%) occurred in this subgroup. A functional...